Genscript Biotech (HKG:1548) unit Nanjing Probio Biotech has granted an exclusive, worldwide, and transferable license to LaNova Medicines allowing it to sublicense certain patents related to anti-PD-1 single domain antibodies and providing it with related know-how to manufacture certain molecules, a Friday bourse filing.
LaNova Medicines has confirmed it will make payments to Nanjing Probio Biotech and Zhenjiang Probio Biotech, another unit of the company, under the agreement.
Under the contract, LaNova Medicines will make certain upfront and milestone payments and share a percentage of sublicense revenue with the company.
LaNova Medicines focuses on discovering and developing innovative biologic drugs that transform cancer treatment.
Shares of the company were up over 6% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。